Literature DB >> 26405345

Ceftolozane/Tazobactam.

Dennis J Cada1, Jesse Wageman2, Danial E Baker3, Terri L Levien4.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The June 2015 monograph topics are ceftazidime-avibactam, isavuconazonium sulfate, panobinostat, levodopa-carbidopa intestinal gel, and LCZ696. The Safety MUE is on ceftazidime-avibactam.

Entities:  

Year:  2015        PMID： 26405345      PMCID： PMC4568114          DOI： 10.1310/hpj5006-526

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  5 in total

1.  Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.

Authors:  Christopher Lucasti; Ellie Hershberger; Benjamin Miller; Sara Yankelev; Judith Steenbergen; Ian Friedland; Joseph Solomkin
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

2.  Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.

Authors:  Benjamin Miller; Ellie Hershberger; David Benziger; Mymy Trinh; Ian Friedland
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

3.  Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.

Authors:  Myra Wooley; Benjamin Miller; Gopal Krishna; Ellie Hershberger; Gurudatt Chandorkar
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

4.  Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.

Authors:  Joseph S Solomkin; John E Mazuski; John S Bradley; Keith A Rodvold; Ellie J C Goldstein; Ellen J Baron; Patrick J O'Neill; Anthony W Chow; E Patchen Dellinger; Soumitra R Eachempati; Sherwood Gorbach; Mary Hilfiker; Addison K May; Avery B Nathens; Robert G Sawyer; John G Bartlett
Journal:  Clin Infect Dis       Date:  2010-01-15       Impact factor: 9.079

5.  Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.

Authors:  Gurudatt Chandorkar; Alan Xiao; Mohamad-Samer Mouksassi; Ellie Hershberger; Gopal Krishna
Journal:  J Clin Pharmacol       Date:  2014-11-14       Impact factor: 3.126
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.